Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations

 Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations

Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson’s Disease

Shots:

  • The company has launched the cobas SARS-CoV-2 variant set 1 test to detect spike mutations in virus variants including UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1)
  • The accurate detection and differentiation of SARS-CoV-2 mutations can aid in assessing the spread of circulating variants and monitor their potential impact on diagnostics, vaccines and therapeutics
  • The cobas SARS-CoV-2 variant set 1 test runs on the high-volume cobas 6800/8800 systems and is for research purposes only. The periodic assessments against emerging variants demonstrated Roche’s test is accurate and effective

Click here ­to­ read full press release/ article | Ref: Roche | Image: Spain’s News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post